Clinical Trials Logo

Clinical Trial Summary

The goal of the proposed project is to determine the safety and tolerability as well as the preliminary efficacy of a novel small molecule drug, S48168 (ARM210), for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT1). This disease is associated with fatal changes in heart rhythms leading to sudden death with exercise or excessive excitement. It is due to mutations in the Ryanodine Receptor calcium release channel, which cause leaky channels leading to the disease. S48168 (ARM210) repairs these leaky channels and can be a disease-modifying therapy restoring normal function to the channels. This result would allow children and adults with CPVT to live normal, active lives.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05122975
Study type Interventional
Source Armgo Pharma, Inc.
Contact Eugene E Marcantonio, MD PhD
Phone 2014633634
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date December 2021
Completion date December 2023